Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V

NCT00097396 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumonic Plague
Preventive Therapy

Interventions

BIOLOGICAL: rF1V vaccine

Sponsor

DynPort Vaccine Company LLC, A GDIT Company